+1 347 708 0418
Targeted Drug ALK Inhibitors for NSCLC market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Targeted Drug ALK Inhibitors for NSCLC market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Company
Pfizer
Novartis
Chugai Pharmaceutical (Hoffmann-La Roche group)
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Alectinib
1.2.5 Brigatinib
1.2.6 Lorlatinib
1.2.7 Other
1.3 Market by Application
1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Perspective (2017-2028)
2.2 Targeted Drug ALK Inhibitors for NSCLC Growth Trends by Region
2.2.1 Targeted Drug ALK Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Region (2017-2022)
2.2.3 Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028)
2.3 Targeted Drug ALK Inhibitors for NSCLC Market Dynamics
2.3.1 Targeted Drug ALK Inhibitors for NSCLC Industry Trends
2.3.2 Targeted Drug ALK Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug ALK Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug ALK Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue (2017-2022)
3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Players (2017-2022)
3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drug ALK Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2021
3.5 Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Area Served
3.6 Key Players Targeted Drug ALK Inhibitors for NSCLC Product Solution and Service
3.7 Date of Enter into Targeted Drug ALK Inhibitors for NSCLC Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Type (2017-2022)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028)
5 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Application (2017-2022)
5.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
6.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
6.2.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
6.2.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
6.2.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
6.3.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
6.3.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
6.3.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
6.4 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
6.4.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
6.4.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
7.2.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
7.2.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
7.2.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
7.3.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
7.3.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
7.3.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
7.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
7.4.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
7.4.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
8.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
8.2.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
8.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
8.3.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
8.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region
8.4.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
9.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
9.2.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
9.2.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
9.2.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
9.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
9.3.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
9.3.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
9.3.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
9.4 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
9.4.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
9.4.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
10.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
10.2.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
10.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
10.3.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
10.4 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
10.4.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Introduction
11.1.4 Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.1.5 Pfizer Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Introduction
11.2.4 Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.2.5 Novartis Recent Developments
11.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
11.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
11.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
11.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Introduction
11.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments
11.4 ARIAD Pharmaceuticals (Takeda)
11.4.1 ARIAD Pharmaceuticals (Takeda) Company Details
11.4.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Introduction
11.4.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.4.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
11.5 Genvio Pharma Limited
11.5.1 Genvio Pharma Limited Company Details
11.5.2 Genvio Pharma Limited Business Overview
11.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
11.5.4 Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.5.5 Genvio Pharma Limited Recent Developments
11.6 Beacon Pharma Limited
11.6.1 Beacon Pharma Limited Company Details
11.6.2 Beacon Pharma Limited Business Overview
11.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
11.6.4 Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.6.5 Beacon Pharma Limited Recent Developments
11.7 Drug International Limted
11.7.1 Drug International Limted Company Details
11.7.2 Drug International Limted Business Overview
11.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Introduction
11.7.4 Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.7.5 Drug International Limted Recent Developments
11.8 Incepta Pharmaceuticals
11.8.1 Incepta Pharmaceuticals Company Details
11.8.2 Incepta Pharmaceuticals Business Overview
11.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Introduction
11.8.4 Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
11.8.5 Incepta Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Crizotinib
Table 3. Key Players of Ceritinib
Table 4. Key Players of Alectinib
Table 5. Key Players of Brigatinib
Table 6. Key Players of Lorlatinib
Table 7. Key Players of Other
Table 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 9. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
Table 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2017-2022)
Table 12. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2023-2028)
Table 14. Targeted Drug ALK Inhibitors for NSCLC Market Trends
Table 15. Targeted Drug ALK Inhibitors for NSCLC Market Drivers
Table 16. Targeted Drug ALK Inhibitors for NSCLC Market Challenges
Table 17. Targeted Drug ALK Inhibitors for NSCLC Market Restraints
Table 18. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Players (2017-2022) & (US$ Million)
Table 19. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players (2017-2022)
Table 20. Global Top Targeted Drug ALK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2021)
Table 21. Ranking of Global Top Targeted Drug ALK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2021
Table 22. Global 5 Largest Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2017-2022)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Targeted Drug ALK Inhibitors for NSCLC Product Solution and Service
Table 25. Date of Enter into Targeted Drug ALK Inhibitors for NSCLC Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 28. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2017-2022)
Table 29. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 30. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2023-2028)
Table 31. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 32. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2017-2022)
Table 33. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 34. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2023-2028)
Table 35. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 36. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 37. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 38. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 39. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 40. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 41. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 42. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 43. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 44. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 45. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 46. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 47. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 48. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 49. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 50. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 51. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
Table 52. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2023-2028) & (US$ Million)
Table 53. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 54. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 55. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 56. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 57. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 58. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 63. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 64. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product
Table 68. Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 69. Pfizer Recent Developments
Table 70. Novartis Company Details
Table 71. Novartis Business Overview
Table 72. Novartis Targeted Drug ALK Inhibitors for NSCLC Product
Table 73. Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 74. Novartis Recent Developments
Table 75. Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
Table 76. Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
Table 77. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product
Table 78. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 79. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments
Table 80. ARIAD Pharmaceuticals (Takeda) Company Details
Table 81. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 82. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product
Table 83. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 84. ARIAD Pharmaceuticals (Takeda) Recent Developments
Table 85. Genvio Pharma Limited Company Details
Table 86. Genvio Pharma Limited Business Overview
Table 87. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
Table 88. Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 89. Genvio Pharma Limited Recent Developments
Table 90. Beacon Pharma Limited Company Details
Table 91. Beacon Pharma Limited Business Overview
Table 92. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
Table 93. Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 94. Beacon Pharma Limited Recent Developments
Table 95. Drug International Limted Company Details
Table 96. Drug International Limted Business Overview
Table 97. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product
Table 98. Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 99. Drug International Limted Recent Developments
Table 100. Incepta Pharmaceuticals Company Details
Table 101. Incepta Pharmaceuticals Business Overview
Table 102. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product
Table 103. Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 104. Incepta Pharmaceuticals Recent Developments
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Type: 2021 VS 2028
Figure 2. Crizotinib Features
Figure 3. Ceritinib Features
Figure 4. Alectinib Features
Figure 5. Brigatinib Features
Figure 6. Lorlatinib Features
Figure 7. Other Features
Figure 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Application: 2021 VS 2028
Figure 9. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 10. Adenocarcinoma of NSCLC Case Studies
Figure 11. Large Cell Carcinoma of NSCLC Case Studies
Figure 12. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Targeted Drug ALK Inhibitors for NSCLC Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region: 2021 VS 2028
Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players in 2021
Figure 17. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2021
Figure 19. North America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 20. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 21. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 22. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 23. United States Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 26. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 27. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 28. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 29. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. France Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. U.K. Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Nordic Countries Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 36. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 37. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 38. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Region (2017-2028)
Figure 39. China Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. India Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 45. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 46. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 47. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 48. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 49. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 52. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 53. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 54. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 55. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. UAE Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 58. Pfizer Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 59. Novartis Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 60. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 61. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 62. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 63. Beacon Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 64. Drug International Limted Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 65. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Buy
